Combination therapies for kidney cancer

The following is a Practice Update interview with Dr Hans Hammers, Associate Professor, Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas. During this interview, Dr Hammers talks about the upcoming combination therapies for the treatment of metastatic renal cell carcinoma (mRCC), such as nivolumab/ipilimumab, axitinib/pembrolizumab, cabozantinib/nivolumab, tivozanib/nivolumab and bevacizumab/atezolizumab combinations currently in development. The clinical trials […]

read more

New insights into immune-related adverse events in genitourinary cancers

The following is an interview with Dr Tanya Dorff, Associate Clinical Professor; Head, GU Cancer Program, City of Hope Hospital, California, where she discusses the results from a study looking at immune-related adverse events (irAEs) with immunotherapy drugs for the treatment of genitourinary cancers. The study that Dr Dorff talks about was presented at the American Society of Clinical Oncology Genitourinary […]

read more

KCSN Trustee appointed as Cancer Research UK Senior Clinical Advisor in clinical research

Cancer Research UK announces the appointment of Dr James Larkin as a new Senior Clinical Advisor in clinical research. Dr Larkin’s new role aims to accelerate the progress of the charity’s clinical research portfolio. He will also support the charity in helping ensure the UK can continue to participate in clinical trials across Europe after […]

read more

Potential role for high dose IL2 in metastatic kidney cancer

The following is an interview with Dr Tanya Dorff, Associate Clinical Professor; Head, GU Cancer Program, City of Hope Hospital, California, where she discusses a potential role for high dose interleukin 2 (IL2) for the treatment of metastatic renal cell carcinoma (mRCC). The study that Dr Dorff talks about was presented at the American Society of Clinical […]

read more

First-line immunotherapy for metastatic kidney cancer

The following is a Practice Update interview with Dr Eric Jonasch, Professor of genitourinary medical oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas. During this interview, Dr Jonasch talks about the upcoming immunotherapy combinations for use in the first-line for the treatment of metastatic renal cell carcinoma (mRCC), as well as […]

read more

Managing adverse events for cancer immunotherapies

Immunotherapy treatments for cancer hold great promise, but also come with their fair share of problems; an increasing number of unique and unexpected adverse events, sometimes appearing long after treatment with immunotherapy ends. The Society for Immunotherapy of Cancer has formed a Toxicity Management Working Group and published a position paper in the Journal of Cancer Immunotherapy in […]

read more
Showing 1 to 6 of 324 results
  TOP